4/24
07:25 pm
exas
Exact Sciences (EXAS) Stock Drops Despite Market Gains: Important Facts to Note [Yahoo! Finance]
Medium
Report
Exact Sciences (EXAS) Stock Drops Despite Market Gains: Important Facts to Note [Yahoo! Finance]
4/24
07:33 am
exas
Here's Why Baron Health Care Fund Reduced Exact Sciences Corporation (EXAS) [Yahoo! Finance]
Low
Report
Here's Why Baron Health Care Fund Reduced Exact Sciences Corporation (EXAS) [Yahoo! Finance]
4/22
01:55 pm
exas
Should You Buy Exact Sciences (EXAS) Ahead of Q1 Earnings? [Yahoo! Finance]
Low
Report
Should You Buy Exact Sciences (EXAS) Ahead of Q1 Earnings? [Yahoo! Finance]
4/17
07:39 pm
exas
Why Exact Sciences (EXAS) Dipped More Than Broader Market Today [Yahoo! Finance]
Medium
Report
Why Exact Sciences (EXAS) Dipped More Than Broader Market Today [Yahoo! Finance]
4/17
11:40 am
exas
Exact Sciences Corporation's (NASDAQ:EXAS) Profit Outlook [Yahoo! Finance]
Low
Report
Exact Sciences Corporation's (NASDAQ:EXAS) Profit Outlook [Yahoo! Finance]
4/15
06:00 am
exas
Exact Sciences Names Aaron Bloomer as New Chief Financial Officer
Medium
Report
Exact Sciences Names Aaron Bloomer as New Chief Financial Officer
4/11
06:00 am
exas
Exact Sciences Announces Debt Exchange Transaction and Private Placement of Convertible Senior Notes
Low
Report
Exact Sciences Announces Debt Exchange Transaction and Private Placement of Convertible Senior Notes
4/10
12:07 am
exas
ZTS, EXAS, AZN: Which Biotech Stock Is the Better Buy? [Yahoo! Finance]
Low
Report
ZTS, EXAS, AZN: Which Biotech Stock Is the Better Buy? [Yahoo! Finance]
4/8
01:30 pm
exas
How This CEO Consumerized Cancer Diagnostics Into A $13B Enterprise [Forbes]
Low
Report
How This CEO Consumerized Cancer Diagnostics Into A $13B Enterprise [Forbes]
4/8
12:13 pm
exas
Exact Sciences to Present Late-Breaking Data from ASCEND-2 Study Validating Its Investigational Multi-Cancer Early Detection Test at AACR Annual Meeting 2024 [Yahoo! Finance]
Low
Report
Exact Sciences to Present Late-Breaking Data from ASCEND-2 Study Validating Its Investigational Multi-Cancer Early Detection Test at AACR Annual Meeting 2024 [Yahoo! Finance]
4/8
12:05 pm
exas
Exact Sciences to Present Late-Breaking Data from ASCEND-2 Study Validating Its Investigational Multi-Cancer Early Detection Test at AACR Annual Meeting 2024
Low
Report
Exact Sciences to Present Late-Breaking Data from ASCEND-2 Study Validating Its Investigational Multi-Cancer Early Detection Test at AACR Annual Meeting 2024
4/8
06:33 am
exas
Global Colorectal Cancer Screening and Diagnostics Industry Research 2023-2033: Colonoscopies and Sigmoidoscopies to Dominate, Advances in Genomics and Molecular Diagnostics, Rise of At-Home Screening [Yahoo! Finance]
Low
Report
Global Colorectal Cancer Screening and Diagnostics Industry Research 2023-2033: Colonoscopies and Sigmoidoscopies to Dominate, Advances in Genomics and Molecular Diagnostics, Rise of At-Home Screening [Yahoo! Finance]
4/8
06:00 am
exas
Exact Sciences Schedules First Quarter 2024 Earnings Call
Low
Report
Exact Sciences Schedules First Quarter 2024 Earnings Call
4/5
03:54 pm
exas
Freenome's colorectal cancer blood test data underwhelm analysts [Yahoo! Finance]
Low
Report
Freenome's colorectal cancer blood test data underwhelm analysts [Yahoo! Finance]
4/4
10:20 am
exas
1 Beaten-Down Cathie Wood Stock to Buy and Hold [Yahoo! Finance]
Low
Report
1 Beaten-Down Cathie Wood Stock to Buy and Hold [Yahoo! Finance]
4/4
06:12 am
exas
Exact Sciences to Provide Mayo Clinic Patients with Individualized Cancer Tumor Information to Inform Treatment [Yahoo! Finance]
Medium
Report
Exact Sciences to Provide Mayo Clinic Patients with Individualized Cancer Tumor Information to Inform Treatment [Yahoo! Finance]
4/4
06:05 am
exas
Exact Sciences to Provide Mayo Clinic Patients with Individualized Cancer Tumor Information to Inform Treatment
Medium
Report
Exact Sciences to Provide Mayo Clinic Patients with Individualized Cancer Tumor Information to Inform Treatment
4/3
12:11 pm
exas
Exact Sciences Co. (NASDAQ: EXAS) had its "buy" rating re-affirmed by analysts at Citigroup Inc.. They now have a $100.00 price target on the stock.
Medium
Report
Exact Sciences Co. (NASDAQ: EXAS) had its "buy" rating re-affirmed by analysts at Citigroup Inc.. They now have a $100.00 price target on the stock.
4/2
12:19 pm
exas
Exact Sciences: Cancer Battle Continues, Shares Likely To Plateau [Seeking Alpha]
Low
Report
Exact Sciences: Cancer Battle Continues, Shares Likely To Plateau [Seeking Alpha]
3/29
01:22 pm
exas
Workflow Services Partners with Exact Sciences to Provide Colorectal Cancer Screening for Patients with Access Challenges at the Pharmacy [Yahoo! Finance]
Low
Report
Workflow Services Partners with Exact Sciences to Provide Colorectal Cancer Screening for Patients with Access Challenges at the Pharmacy [Yahoo! Finance]
3/29
12:57 pm
exas
Exact Sciences, Mayo Clinic share early data on esophageal cancer test [Yahoo! Finance]
Low
Report
Exact Sciences, Mayo Clinic share early data on esophageal cancer test [Yahoo! Finance]
3/28
03:15 pm
exas
Exact Sciences gains after data for novel cancer screening test [Seeking Alpha]
Low
Report
Exact Sciences gains after data for novel cancer screening test [Seeking Alpha]
3/28
06:09 am
exas
Exact Sciences Advances Development of Non-Endoscopic Oncoguard® Esophagus Test to Screen for Esophageal Cancer and Pre-Cancer [Yahoo! Finance]
Medium
Report
Exact Sciences Advances Development of Non-Endoscopic Oncoguard® Esophagus Test to Screen for Esophageal Cancer and Pre-Cancer [Yahoo! Finance]
3/28
06:00 am
exas
Exact Sciences Advances Development of Non-Endoscopic Oncoguard® Esophagus Test to Screen for Esophageal Cancer and Pre-Cancer
Medium
Report
Exact Sciences Advances Development of Non-Endoscopic Oncoguard® Esophagus Test to Screen for Esophageal Cancer and Pre-Cancer
3/27
08:13 am
exas
Exact Sciences Named 2024 Gallup Exceptional Workplace Award Winner [Yahoo! Finance]
Low
Report
Exact Sciences Named 2024 Gallup Exceptional Workplace Award Winner [Yahoo! Finance]